One patient with a rare brain lymphoma stayed cancer free for more than 3 years
Original title: Primary CNS Anaplastic Large Cell Lymphoma DUPS22 Rearranged with Gain of ALK: A Case Report and Review of the Literature.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This is a report about a single patient, not a study, so it does not prove anything about treatment.
The short version
Doctors report one person with a rare brain lymphoma who stayed in remission for more than 3 years after standard treatment.
What was studied. This is a report about one patient. The patient had a rare lymphoma in the brain called ALK-negative anaplastic large cell lymphoma. Doctors tested the tumor and found two gene changes, a DUSP22-IRF4 rearrangement and extra copies of the ALK gene.
What they found. The patient was treated with high-dose methotrexate, a chemotherapy drug, and then had radiation to the whole brain. Treatment was complicated by a liver problem. The cancer stayed away for more than 3 years, and the authors believe this is the first report of these gene changes in a brain lymphoma.
What this means, and what it doesn't
What it could mean: This type of brain lymphoma usually has poor survival. This report describes one person who did well for years using treatments doctors already give. It raises the question of whether gene testing of the tumor could help doctors understand a person's outlook.
What it doesn't mean: This is a report about one patient, not a study in a group of people. One person's result does not tell us what will happen for anyone else. No new drug or new treatment was tested here. It does not mean these gene changes lead to a good outcome for everyone with this lymphoma. It is not a cure.
Source: PubMed, July 17, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.